New­ly Nas­daq-list­ed Cal­lid­i­tas surges af­ter lead kid­ney drug hits pri­ma­ry end­point

Cal­lid­i­tas still hasn’t proven to pa­tients that their kid­ney drug has long-term ben­e­fits, but the com­pa­ny says they’ve seen more than enough to go to reg­u­la­tors.

The Swedish com­pa­ny, which re­cent­ly raised a $90 mil­lion Nas­daq IPO,  an­nounced on Sun­day that their lead drug Ne­fe­con had hit pri­ma­ry and sec­ondary end­points in the first part of a Phase III tri­al, suc­cess­ful­ly im­prov­ing kid­ney func­tion in pa­tients with an in­flam­ma­to­ry kid­ney dis­ease called pri­ma­ry IgA nephropa­thy. They will use the da­ta to ask the FDA and EMA for ac­cel­er­at­ed ap­proval in the first quar­ter of 2021, part of a two-pronged strat­e­gy they laid out in their F-1 ear­li­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER